Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Veeva Systems Inc.
25.1% sales growth and 18.73% return on equity
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America.
Veeva Systems Inc.’s sales growth this year is expected to be 31.2% and 18.6% for next year.
Year-on-year quarterly revenue growth grew by 34.4%, now sitting on 1.38B for the twelve trailing months.
Veeva Systems Inc.’s sales growth for the next quarter is 25.1%. The company’s growth estimates for the ongoing quarter and the next is 25.9% and 10.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.73%.
Volatility
Veeva Systems Inc.’s last day, last week, and last month’s average volatility was 4.06%, 1.18%, and 0.33%, respectively.
Veeva Systems Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.89%, 3.17%, and 3.34%, respectively.
Veeva Systems Inc.’s Stock Yearly Top and Bottom Value
Veeva Systems Inc.’s stock is valued at $288.54 at 04:22 EST, below its 52-week high of $313.99 and way above its 52-week low of $118.11.
Veeva Systems Inc.’s Moving Average
Veeva Systems Inc.’s worth is above its 50-day moving average of $273.73 and above its 200-day moving average of $270.44.
2. Advanced Semiconductor Engineering, Inc.
19.9% sales growth and 11.61% return on equity
ASE Technology Holding Co., Ltd.
Advanced Semiconductor Engineering, Inc.’s sales growth this year is anticipated to be 20.5% and 8.5% for next year.
Year-on-year quarterly revenue growth grew by 4.8%, now sitting on N/A for the twelve trailing months.
Advanced Semiconductor Engineering, Inc.’s sales growth for the next quarter is 19.9%. The company’s growth estimates for the current quarter and the next is a negative 0% and negative -20%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.61%.
Volatility
Advanced Semiconductor Engineering, Inc.’s last day, last week, and last month’s average volatility was 1.74%, 2.32%, and 0.55%, respectively.
Advanced Semiconductor Engineering, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.04%, 2.42%, and 1.95%, respectively.
Advanced Semiconductor Engineering, Inc.’s Stock Yearly Top and Bottom Value
Advanced Semiconductor Engineering, Inc.’s stock is valued at $6.57 at 04:22 EST, way under its 52-week low of $3.17.
Advanced Semiconductor Engineering, Inc.’s Moving Average
Advanced Semiconductor Engineering, Inc.’s worth is way above its 50-day moving average of $5.60 and way above its 200-day moving average of $4.75.
3. Eli Lilly and Company
13.7% sales growth and 131.77% return on equity
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide.
Eli Lilly and Company’s sales growth this year is expected to be 9.3% and 12.3% for next year.
Year-on-year quarterly revenue growth grew by 4.8%, now sitting on 23.21B for the twelve trailing months.
Eli Lilly and Company’s sales growth for the next quarter is 13.7%. The company’s growth estimates for the ongoing quarter and the next is 35.8% and 13.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 131.77%.
Volatility
Eli Lilly and Company’s last day, last week, and last month’s average volatility was a positive 0.35%, a negative 0.29%, and a positive 0.53%, respectively.
Eli Lilly and Company’s last day, last week, and last month’s high and low average amplitude percentage was 1.35%, 2.66%, and 2.34%, respectively.
Eli Lilly and Company’s Stock Yearly Top and Bottom Value
Eli Lilly and Company’s stock is valued at $166.41 at 04:22 EST, below its 52-week high of $173.90 and way higher than its 52-week low of $117.06.
Eli Lilly and Company’s Moving Average
Eli Lilly and Company’s value is above its 50-day moving average of $158.00 and above its 200-day moving average of $152.89.
Previous days news about Eli Lilly and Company
According to Business Insider on Monday, 11 January, "Boehringer Ingelheim and Eli Lilly and Company (LLY) announced the FDA has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) for adults with heart failure with reduced ejection fraction. "
According to Business Insider on Monday, 11 January, "Shares of drug maker Eli Lilly and Company (LLY) are climbing more than 11% Monday morning on the news of FDA accepting supplemental New Drug Application for its type 2 diabetes treatment Jardiance."
According to MarketWatch on Wednesday, 13 January, "They include Johnson & Johnson at No. 24 , Pfizer at No. 39 and Eli Lilly and Company at No. 87."
4. Triumph Bancorp, Inc.
10.6% sales growth and 7.32% return on equity
Triumph Bancorp, Inc. operates as a financial holding company for TBK Bank, SSB that provides banking and commercial finance products and services to retail customers and small-to-mid-sized businesses in the United States.
Triumph Bancorp, Inc.’s sales growth this year is expected to be 8.8% and 6.2% for next year.
Year-on-year quarterly revenue growth grew by 22.2%, now sitting on 280.17M for the twelve trailing months.
Triumph Bancorp, Inc.’s sales growth for the next quarter is 10.6%. The company’s growth estimates for the ongoing quarter and the next is 22.7% and 427.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.32%.
Volatility
Triumph Bancorp, Inc.’s last day, last week, and last month’s average volatility was 0.44%, 3.83%, and 1.03%, respectively.
Triumph Bancorp, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.43%, 5.89%, and 4.77%, respectively.
Triumph Bancorp, Inc.’s Stock Yearly Top and Bottom Value
Triumph Bancorp, Inc.’s stock is valued at $60.22 at 04:22 EST, under its 52-week high of $60.79 and way above its 52-week low of $19.03.
Triumph Bancorp, Inc.’s Moving Average
Triumph Bancorp, Inc.’s worth is way higher than its 50-day moving average of $49.60 and way above its 200-day moving average of $36.78.
5. New York Community Bancorp, Inc.
25.3% sales growth and 6.29% return on equity
New York Community Bancorp, Inc. operates as a bank holding company for New York Community Bank that provides banking products and services in Metro New York, New Jersey, Ohio, Florida, and Arizona.
New York Community Bancorp, Inc.’s sales growth this year is anticipated to be 15% and 15.2% for next year.
Year-on-year quarterly revenue growth grew by 10.6%, now sitting on 1.05B for the twelve trailing months.
New York Community Bancorp, Inc.’s sales growth for the next quarter is 25.3%. The company’s growth estimates for the current quarter and the next is 30% and 30%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.29%.
Volatility
New York Community Bancorp, Inc.’s last day, last week, and last month’s average volatility was a negative 0.73%, a positive 0.65%, and a positive 0.32%, respectively.
New York Community Bancorp, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.32%, 2.61%, and 2.50%, respectively.
New York Community Bancorp, Inc.’s Stock Yearly Top and Bottom Value
New York Community Bancorp, Inc.’s stock is valued at $10.89 at 04:22 EST, below its 52-week high of $11.90 and way above its 52-week low of $7.72.
New York Community Bancorp, Inc.’s Moving Average
New York Community Bancorp, Inc.’s value is above its 50-day moving average of $10.20 and way higher than its 200-day moving average of $9.45.
6. Vertex Pharmaceuticals Incorporated
8.3% sales growth and 40.2% return on equity
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis.
Vertex Pharmaceuticals Incorporated’s sales growth this year is anticipated to be 53.3% and 12.9% for next year.
Year-on-year quarterly revenue growth grew by 62%, now sitting on 5.99B for the twelve trailing months.
Vertex Pharmaceuticals Incorporated’s sales growth for the next quarter is 8.3%. The company’s growth estimates for the current quarter and the next is 51.2% and 4.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 40.2%.
Volatility
Vertex Pharmaceuticals Incorporated’s last day, last week, and last month’s average volatility was a negative 2.29%, a positive 0.07%, and a positive 0.11%, respectively.
Vertex Pharmaceuticals Incorporated’s last day, last week, and last month’s high and low average amplitude percentage was 4.16%, 3.10%, and 2.51%, respectively.
Vertex Pharmaceuticals Incorporated’s Stock Yearly Top and Bottom Value
Vertex Pharmaceuticals Incorporated’s stock is valued at $229.38 at 04:22 EST, way below its 52-week high of $306.08 and way higher than its 52-week low of $197.47.
Vertex Pharmaceuticals Incorporated’s Moving Average
Vertex Pharmaceuticals Incorporated’s worth is below its 50-day moving average of $229.55 and below its 200-day moving average of $252.49.
7. ConnectOne Bancorp, Inc.
11.1% sales growth and 8.25% return on equity
ConnectOne Bancorp, Inc. operates as the bank holding company for ConnectOne Bank, a state chartered bank that provides various commercial banking products and services.
ConnectOne Bancorp, Inc.’s sales growth this year is anticipated to be 27.2% and a negative 0.1% for next year.
Year-on-year quarterly revenue growth grew by 20.6%, now sitting on 200.76M for the twelve trailing months.
ConnectOne Bancorp, Inc.’s sales growth for the next quarter is 11.1%. The company’s growth estimates for the present quarter and the next is a negative 11.5% and 71.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.25%.
Volatility
ConnectOne Bancorp, Inc.’s last day, last week, and last month’s average volatility was a negative 4.56%, a positive 1.07%, and a positive 0.25%, respectively.
ConnectOne Bancorp, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 7.22%, 5.07%, and 3.62%, respectively.
ConnectOne Bancorp, Inc.’s Stock Yearly Top and Bottom Value
ConnectOne Bancorp, Inc.’s stock is valued at $20.85 at 04:22 EST, way under its 52-week high of $25.67 and way above its 52-week low of $8.86.
ConnectOne Bancorp, Inc.’s Moving Average
ConnectOne Bancorp, Inc.’s worth is higher than its 50-day moving average of $19.67 and way higher than its 200-day moving average of $16.18.
8. Perficient, Inc.
10.7% sales growth and 8.88% return on equity
Perficient, Inc. provides digital consultancy services and solutions in the United States.
Perficient, Inc.’s sales growth this year is expected to be 7.7% and 9.5% for next year.
Year-on-year quarterly revenue growth grew by 9%, now sitting on 594.74M for the twelve trailing months.
Perficient, Inc.’s sales growth for the next quarter is 10.7%. The company’s growth estimates for the current quarter and the next is 20.7% and 23.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.88%.
Volatility
Perficient, Inc.’s last day, last week, and last month’s average volatility was a negative 3.06%, a positive 0.37%, and a negative 0.02%, respectively.
Perficient, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.11%, 3.05%, and 2.46%, respectively.
Perficient, Inc.’s Stock Yearly Top and Bottom Value
Perficient, Inc.’s stock is valued at $47.32 at 04:22 EST, way below its 52-week high of $53.76 and way higher than its 52-week low of $18.88.
Perficient, Inc.’s Moving Average
Perficient, Inc.’s value is under its 50-day moving average of $47.53 and way higher than its 200-day moving average of $42.88.
